Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT04471727
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
- NCT04471727 ↗
- Active, not recruiting
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Focused
We haven't built an HCP commentary report on NCT04471727 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04471727 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3).
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Small-Cell Lung Cancer; Neuroendocrine Carcinoma
- Interventions
- Gocatamig; Atezolizumab; Ifinatamab Deruxtecan (I-DXd)
- Arms
- Gocatamig monotherapy dose escalation with 1 week dosing interval · Experimental
- Gocatamig monotherapy dose escalation with 2 week dosing interval · Experimental
- Gocatamig monotherapy dose escalation with 3 week dosing interval · Experimental
- Gocatamig dose escalation with atezolizumab · Experimental
- Gocatamig dose escalation in combination with I-DXd · Experimental
- Enrollment
- 232 (estimated)
- Primary outcomes
- Percentage of participants who experience an adverse event
- Percentage of participants who discontinue due to an adverse event
- Number of participants with dose limiting toxicity (DLT) following treatment with HPN328 as monotherapy or in combination with atezolizumab or I-DXd
- Maximum concentration (Cmax) of Gocatamig
- Cmax of Atezolizumab
- Cmax of I-DXd
- Time to maximum concentration (Tmax) of Gocatamig
- Tmax of atezolizumab
- Tmax of I-DXd
- Area under the concentration-time curve over the dosing interval t (AUCt) of Gocatamig
- AUCt of atezolizumab
- AUCt of I-DXd
- Area under the concentration-time curve extrapolated to infinity (AUCinf) of Gocatamig
- AUCinf of atezolizumab
- AUCinf of I-DXd
- Terminal half-life (t1/2) of Gocatamig
- t1/2 of atezolizumab
- t1/2 of I-DXd
- Single dose clearance (CL) of Gocatamig
- CL of atezolizumab
- CL of I-DXd
- Steady state maximum concentration (Cmax,ss) of Gocatamig
- Cmax,ss of atezolizumab
- Cmax,ss of I-DXd
- Steady state Ctrough (Ctrough,ss) of Gocatamig
- Ctrough,ss of atezolizumab
- Ctrough,ss of I-DXd
- Steady state time to maximum concentration (Tmax,ss) of Gocatamig
- Tmax,ss of atezolizumab
- Tmax,ss of I-DXd
- Area under the steady state concentration-time curve over dosing interval t (AUCt,ss) of Gocatamig
- AUCt,ss of atezolizumab
- AUCt,ss of I-DXd
- Steady state t1/2 (t1/2,ss) of Gocatamig
- t1/2,ss of Gocatamig with atezolizumab
- t1/2,ss of IDXd
- Steady state CL (CL,ss) of Gocatamig
- CL,ss of Gocatamig with atezolizumab
- CL,ss of I-DXd
- Steady state volume of distribution (V,ss) of Gocatamig
- V,ss of atezolizumab
- V,ss of I-DXd
- Steady state accumulation ratio (AC) of Gocatamig
- AC of atezolizumab
- AC of I-DXd
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) with Daiichi Sankyo
- Start
- Dec 14, 2020
- Primary completion
- Jan 28, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04471727 · updated Feb 24, 2026